5 Takeaways From The HER2 Inhibitors Market Overview 2023
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032
According to The Business Research Company’s HER2 Inhibitors Global Market Report 2023, the HER2 inhibitors market is expected to show promising growth in the forecast period.
The global HER2 inhibitors market has demonstrated impressive growth, surging from $7.26 billion in 2022 to $7.98 billion in 2023, showcasing a robust compound annual growth rate (CAGR) of 9.9%. As we look ahead, projections paint a promising picture, with the market size expected to reach $11.5 billion in 2027, fueled by a sustained CAGR of 9.6%.
Catalyst for Growth: Surge in Breast Cancer Cases
The burgeoning number of breast cancer cases worldwide stands as a pivotal factor propelling the growth of the HER2 inhibitors market. Key contributors to this surge include:
- American Landscape: In the US alone, as of January 2020, more than 3.5 million women had a history of breast cancer, including those currently under treatment or having completed their regimen, as per the American Cancer Society.
- Global Impact: According to the World Health Organization (WHO), breast cancer affected a staggering 2.3 million women globally in 2020, resulting in 685,000 fatalities.
Market Players: Powerhouses in HER2 Inhibition
Major players steering the HER2 inhibitor market include:
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Puma Biotechnology Inc.
Strategic Collaborations: Fueling Innovation
Biotechnology companies, keen on expanding their HER-2 inhibitor portfolios, are increasingly opting for collaborations and partnerships. Notable examples include:
- Alphamab Oncology and Sanofi: In June 2020, Alphamab Oncology collaborated with Sanofi to investigate KN026, a HER2 inhibitor, in combination with other drugs for HER2 breast cancer treatment.
Market Segmentation: Understanding Diversity
The global HER2 inhibitors market is segmented based on:
- Combination Therapy
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Breast Cancer
- Other Applications
- End User:
- Other End Users
Regional Dynamics: North America Leading, Middle East Rising
As of 2022, North America claimed the throne as the largest region in the HER2 inhibitors market. However, the Middle East is poised to emerge as the fastest-growing region during the forecast period, signifying the global nature of market dynamics.
View More On The HER2 Inhibitors Market Report 2023 – https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Request A Sample Of The Global HER2 Inhibitors Market Report 2023:
The HER2 Inhibitors Global Market Report 2023 offers a comprehensive overview on the HER2 inhibitors market size, growth rate, trends and drivers, opportunities, strategies, and competitor landscape. The countries covered in the HER2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.
The Table Of Content For The HER2 Inhibitors Market Include:
1. HER2 Inhibitors Market Executive Summary
2. HER2 Inhibitors Market Segments
3. HER2 Inhibitors Market Size And HER2 Inhibitors Market Growth Rate
4. Key HER2 Inhibitors Market Trends
5. Major HER2 Inhibitors Market Drivers
25. Key Mergers And Acquisitions In The HER2 Inhibitors Market
26. Top HER2 Inhibitors Companies
27. HER2 Inhibitors Market Opportunities And Strategies
28. HER2 Inhibitors Market, Conclusions And Recommendations
Follow us on:
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model